drugset / Trial / NCT00722176

Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020

NCT00722176

Phase 2 Completed 220 enrolled BioLineRx, Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Six-Week, Randomized, Double-Blind, Parallel Group Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020 Compared To Risperidone, In Schizophrenic Patients Previously Treated In Study Bl-1020 Iib For A Maximum Of Six Weeks With Bl-1020 (High Dose, Low Dose), Risperidone Or Placebo

Timeline

Start
2008-06
Primary completion
2009-07
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject PERPHENAZINE 4-AMINOBUTYRATE Small molecule 10 mg Oral
Subject PERPHENAZINE 4-AMINOBUTYRATE Small molecule 30 mg Oral
Comparator Risperidone Other / unclassified 8 mg Oral

Indications